Skip to main content

Table 1 Most important peer reviewed published papers in the last 10 years

From: Low Dose Medicine: theoretical background and scientific evidence

Year

Authors

Journal

Study Type

Title

Molecules and Tested Drugs

2009

Gariboldi S. et al. [26]

Pulmonary Pharmacology & Therapeutics

In vivo basic research

Low dose oral administration of cytokines for treatment of allergic asthma

IL-12

IFN-γ

2012

D’amico L. et al. [27]

Journal of Cancer Therapy

Ex vivo basic research

Low Dose of IL-12 stimulates T Cell response in cultures of PBMCs derived from Non-Small Cell Lung Cancer Patients

IL-12

2013

Cardani D. et al. [28]

Gastroenterology Research

In vivo basic research

Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation.

IL-10

Antibodies-anti IL-1

2014

Radice E. et al. [29]

International Immunopharmacology

Ex vivo basic research

Low-doses of sequential-kinetic-activated interferon-gamma enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study

IFN-γ

2014

Roberti ML. et al. [30]

Journal of Biological Regulatory & Homeostatic Agents

Clinical trial

Immunomodulating treatment with low dose Interleukin-4, Interleukin-10 and Interleukin-11 in psoriasis vulgaris.

IL-4

IL-10

IL-11

2015

Luchetti P. [31]

Minerva Medica Oftalmologica

Clinical trial

Increasing of visual function in patients with retinal atrophy treated with drugs of Low Dose Medicine. Monocentric retrospective observational study.

NT3

NT4

NGF

Retina suis Injeel

Solanum compositum

Ubichinon compositum

2015

Barygina V. et al. [32]

Journal of Dermatological Science

In vitro basic research

Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin.

IL-4

IL-10

b-FGF

β-endorphin

2015

Lotti T. et al. [33]

Journal of Biological Regulatory & Homeostatic Agents

Clinical trial

Vitiligo: successful combination treatment based on oral low dose cytokines and different topical treatments.

IL-4

IL-10

Antibodies-anti IL-1

b-FGF

2015

Radice E. et al. [34]

Translational Oncology

Ex vivo basic research

Enhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12.

IL-4

IL-12

2015

Lotti T. et al. [35]

Der Hautarzt

Clinical trial

Successful combination treatment for psoriasis with phototherapy and low-dose cytokines: A spontaneous, retrospective observational clinical study.

IL-4

IL-10

Antibodies-anti IL-1

2016

Barygina V. et al. [36]

Journal of Dermatological Science

In vitro basic research

Low dose cytokines reduce oxidative stress in primary lesional fibroblasts obtained from psoriatic patients.

IL-4

IL-10

b-FGF

β-endorphin

2016

Fiorito F. et al. [37]

Comparative Immunology, Microbiology and Infectious Diseases

Clinical trial (veterinary)

Clinical improvement in feline herpesvirus 1 infected cats by oral low dose of interleukin-12 plus interferon-gamma.

IL-12

IFN-γ

2016

Genazzani A. et al. [38]

Bollettino di Ginecologia Endocrinologica

Frontiers in Gynecological Endocrinology

Observational pilot study

Pharmacological and Integrative Treatment of Stress-Induced Hypothalamic Amenorrhea

Beta-Estradiol

2017

Martin Martin LS. et al. [39]

Drug Design, Development and Therapy

Clinical trial

An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis.

Antibodies-anti IL-1

IL-10

IL-4

2017

Castiglioni S. et al. [40]

International Journal

of Molecular Sciences

In vitro basic research

Femtograms of Interferon- γ Suffice to Modulate the Behavior of Jurkat Cells: A New Light in Immunomodulation

IFN-γ

2018

Mancini F. et al. [41]

International Immunopharmacology

In vitro basic research

Low-dose SKA Progesterone and Interleukin-10 modulate the inflammatory pathway in endometriotic cell lines

Progesterone

IL-10